Valneva SE (VALN)
| Market Cap | 504.43M |
| Revenue (ttm) | 166.26M |
| Net Income (ttm) | -26.51M |
| Shares Out | 69.58M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | 10,000.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,424 |
| Open | 7.15 |
| Previous Close | 7.12 |
| Day's Range | 7.11 - 7.60 |
| 52-Week Range | 6.58 - 16.49 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 21.50 (+195.33%) |
| Earnings Date | May 7, 2024 |
About VALN
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by c... [Read more]
Financial Performance
In 2023, Valneva SE's revenue was 153.71 million, a decrease of -57.46% compared to the previous year's 361.30 million. Losses were -101.43 million, -29.21% less than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 195.33% from the latest price.
News
Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®
Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorizati...
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
Saint-Herblain (France), June 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors wer...
Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ®
Saint-Herblain (France), June 24, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva's single-dose vac...
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Saint-Herblain (France), June 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined ...
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
Saint-Herblain (France), June 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor confe...
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vac...
Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine
Saint Herblain (France), May 31, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of t...
EU regulator recommends use of Valneva's chikungunya vaccine
The European Medicines Agency (EMA) recommended the use of Valneva's single-shot vaccine for chikungunya virus, the regulator said on Friday.
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scienti...
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine comp...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipa...
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration...
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
Saint-Herblain (France), March 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, ...
French biotech company Valneva raises product sales guidance
French biotech company Valneva on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 million to $206.45 million) i...
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26% Excluding COVID-19 vaccine sales, product sal...
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare invest...
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Saint-Herblain (France), March 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate at upcoming investor c...
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ ®
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance Total revenues of €153.7 million, including product sales of €144.6 million Product sales surpassed pre-pandemic (2019) sa...
Valneva sells chikungunya vaccine priority review voucher for $103 mln
French vaccine maker Valneva said on Monday it sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million.
Valneva Announces Sale of Priority Review Voucher for $103 Million
Saint-Herblain (France), February 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the ...
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
Saint-Herblain (France), January 10, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the s...
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
Saint-Herblain (France), January 4, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach,...
Valneva Provides Updated 2023 Financial Guidance
Saint-Herblain (France), December 29, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company is modifying its financial guidance for 2023....